Related Experiment Video

Updated: Aug 5, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

Successful propranolol therapy for infantile hepatic hemangioma with cardiac failure

Fadhel Al Ateeqi1, Ala K Shaikhkhalil2, Haitham Talo3,4

  • 1Department of Pediatrics Danat Al Emarat Hospital for Women and Children Abu Dhabi United Arab Emirates.

JPGN Reports
|July 25, 2026
PubMed

Insights

Infantile hepatic hemangioma (IHH) is a serious condition. Propranolol effectively treats symptomatic IHH, leading to rapid improvement in infants and highlighting the need for early multidisciplinary care.

Area of Science:

  • Pediatric Hepatology
  • Neonatal Cardiology
  • Clinical Pharmacology

Background:

  • Infantile hepatic hemangioma (IHH) can lead to life-threatening complications like high-output cardiac failure and growth faltering.
  • Current treatment strategies for IHH lack standardization, necessitating effective therapeutic options.

Purpose of the Study:

  • To report a case of multifocal infantile hepatic hemangioma (IHH) presenting with severe complications.
  • To evaluate the efficacy and safety of propranolol as a first-line treatment for symptomatic IHH.

Main Methods:

  • A case report of a female infant diagnosed with multifocal IHH.
  • Clinical assessment and radiological imaging before and during propranolol therapy.

Main Results:

  • The infant presented with high-output cardiac failure, hepatomegaly, and growth faltering.
  • Propranolol therapy resulted in rapid and sustained clinical and radiological improvement.

Conclusions:

  • Propranolol is a safe and effective first-line therapy for symptomatic infantile hepatic hemangioma (IHH).
  • Early diagnosis and multidisciplinary management are crucial for optimal outcomes in infants with IHH.

Keywords:
beta blockerliver hemangiomapediatric liver tumors

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...